Clearpoint Neuro's Big Bet on Gene Therapy Delivery Takes a Hit — But Is the Selloff Overdone?

Shares of Clearpoint Neuro cratered 15.8% to $12.88 Tuesday morning after partner uniQure reported that its Huntington's disease gene therapy showed a weaker treatment effect at four years than it did at three — a result that directly threatens the biggest growth story underpinning Clearpoint's stock.

The Drug Data That Spooked the Market

The 48-month data showed only a 44% reduction in disease progression, which failed to reach statistical significance — a steep decline from the statistically significant 75% slowing reported at 36 months (p=0.003) . UniQure slumped in early trading , dropping 48% to $20.50 premarket . uniQure blames the miss partly on a flawed comparison group: 53% of patients in the external control dataset had dropped out by 48 months, and those who left were progressing faster, likely understating the therapy's apparent benefit .

Why a Partner's Miss Hits Clearpoint's Revenue Line Clearpoint makes the MRI-guided navigation platform and specialized delivery cannula used to inject the gene therapy directly into the brain. Each procedure generates $15,000 to $25,000 in equipment and cannula revenue per patient . If the drug fails to win approval or its commercial rollout shrinks, that per-procedure revenue evaporates. Clearpoint's biologics and drug delivery segment already fell to $4.0 million in Q2 2026 from $4.7 million a year earlier , making the uniQure pipeline even more critical to growth.

The FDA Lifeline — and Its Limits Crucially, the FDA agreed that the stronger 36-month data could serve as the primary basis for uniQure's approval application, and the filing was submitted before today's disappointing results . That means the approval path isn't dead — but a confirmatory study using the now-weakened 48-month measure will face intense scrutiny. The FDA has already pushed uniQure to conduct a randomized, controlled trial , adding years and cost.

Cash Runway Adds Pressure

Clearpoint held just $29.4 million in cash as of June 30 and burned roughly $16.5 million in the first half of 2026 . The stock traded at a premium 8x enterprise-value-to-sales ratio , justified largely by expectations of partner drug launches. With its largest partner program now in question and Q2 revenue of $10.9 million already missing consensus by $1.83 million , that premium valuation faces a hard test.